focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Indivior, Diurnal start trials; Alien Metals tests

Wed, 01st Jun 2022 19:41

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Power Metal Resources PLC - metals exploration company focused in North America, Africa and Australia - Says its subsidiary First Development Resources raised GBP1.1 million through a Pre-IPO financing undertaken with SI Capital Ltd. It issued 16.9 million shares at a price of 6.67p pence per share, which will represent 27% of its issued share capital on completion of the financing. "The pre-IPO financing provides FDR with the necessary working capital to confidently push ahead with business operations including its planned listing on the London capital markets," First Development Resources Chief Executive Tristan Pottas says.

----------

Benchmark Holdings PLC - Sheffield, England-based aquaculture genetics, health and nutrition company - Converts existing NOK190 million, equal to GBP16 million, loan with Nordea Bank related to its Genetics salmon egg facility in Salten, Norway into a green loan. The new green loan remains as ring-fenced debt without recourse to the remainder of the Benchmark Group and has a marginally lower interest rate, it says.

----------

Globalworth Real Estate Investments Ltd - office investor in central and eastern Europe - Enters into a six-year term loan agreement for EUR85 million with the International Finance Corp, which is a member of the World Bank. Board of Globalworth considers that the loan will further strengthen the company's liquidity position and provide flexible capital on "attractive terms".

----------

Sovereign Metals Ltd - Perth, Scotland-based rutile exploration and development company focused in Malawi - Starts pre-feasibility study drilling program across the Kasiya Rutile project. Says 12,000 metres drilling program commenced at Kasiya to upgrade higher-grade mineral resource areas to underpin conversion to reserves as part of the planned PFS

----------

Mosman Oil & Gas Ltd - Sydney-based oil and gas company with projects in Australia and the US - Says its net production for the three months to March 31 totalled 11,756 barrels of oil equivalent, will update on quarterly production again in July.

----------

Calculus VCT PLC - invests in UK growth companies - Net asset value per share as at February 28 rises to 67.90p from 67.08p on the same date a year before. Annual yield remains flat at 4.50%, year-on-year. Lifts final dividend to 3.06p from 3.02p. Cautions about " negative economic consequences" from conflict in Ukraine.

----------

APQ Global Ltd - Guernsey-based emerging markets investor - Revenue for 2021 falls to USD6.9 million from USD11.4 million in 2020. Pretax loss narrows to USD7.6 million from USD40.4 million, as the net loss on financial assets at fair value drops. Believes its Direct Investment Portfolio is now "very well positioned to capitalise from several growing trends globally."

----------

RiverFort Global Opportunities PLC - High Wycombe, England-based capital market company - Notes takeover offer for Pires Investments PLC from Tern PLC. Says the offer values its stake of 30.9 million shares in Pires at GBP2.5 million. an irrevocable undertaking in connection with the offer relating to all the shares and warrants in Pires held by it.

----------

Novacyt SA - Surrey-based biotechnology group focused on clinical diagnostics - Receives approval for its PROmate Covid-19 1G PCR test from the Coronavirus Test Device Approvals regulation. Its PathFlow Covid-19 rapid antigen test also receives a CE mark, approving it for sales in all 30 European Economic Area countries.

----------

Bluefield Solar Income Fund Ltd - Guernsey, UK-based investment company focused on low-carbon assets in the UK - Raises GBP150 million via issue of 115.4 million new ordinary shares. The new shares represent 23% of the company's share capital prior to the placing, and bring its enlarged share capital to 611.5 million shares. The funds will be used to pay down its revolving credit facility, which as of May 10 was fully overdrawn.

----------

IOG PLC - North Sea-focused gas and infrastructure operator - Says production at Saturn Banks resumed on May 31, at an initial level of 30 million cubic feet of gas per day. This follows an announcement on May 23 that production had shut down at Saturn Banks facility due to a drainage fault in the terminal condensate stabilisation unit's two compressors. IOG now expects production to be "gradually" restored to its prior levels of around 55-66 million cubic feet of gas per day over the coming weeks. "IOG, Perenco and ODE Asset Management have collaborated well to facilitate rapid execution of the PUK terminal modification and allow our production to be resumed at 30 mmscf/d. We look forward to a phased build up to double that level as fast as technically feasible over the coming weeks," says Chief Executive Officer Andrew Hockey.

----------

Atrato Onsite Energy PLC - London-based renewable energy investment trust - Invests GBP6.6 million into operational rooftop solar photovoltaic system for Marks & Spencer PLC. Expects asset to become immediately income-producing via the sale of green electricity onsite under a long-term power purchase agreement with M&S. The PV system is installed on the M&S logistics warehouse in Leicestershire, providing 6.1 megawatt peak capacity.

----------

Indivior PLC - Virginia, US-base pharmaceutical company - Enrols first patient in phase 2b study of AEF0117 for the treatment of cannabis use disorder. "Following the promising results of a Phase 2a study showing that AEF0117 reduced the subjective effects of cannabis and cannabis self-administration in subjects with moderate to severe CUD, this Phase 2b clinical trial aims at demonstrating the efficacy, tolerability and safety of AEF0117 for the treatment of CUD," said Chief Scientific Officer Christian Heidbreder.

----------

Angus Energy PLC - UK-focused oil and gas development company - Completes acquisition of Saltfleetby Energy Ltd, giving it 100% interest in the Saltfleetby license in East Lindsey district of Lincolnshire, England. "It is the board's view that the acquisition and associated share issuance, taken in totality, will be highly accretive for Angus shareholders this year and in the years following. The acquisition...doubles the value of Angus' interest in the Saltfleetby Licence to approximately GBP50 million on the basis that the Competent Persons Report of October 2021 ascribed a conservative GBP25.4 million P90 valuation to Angus' 51% interest in October after all associated debt funding was taken into account," CEO George Lucan comments.

----------

Alien Metals Ltd - London-based mineral exploration company focused on Australia, Mexico and Greenland - Says metallurgical test work programme at Hancock iron ore project shows high-grade and low-impurity nature of the deposit. In light of this, Alien advances discussions with potential offtake partners, and delivers marketing samples. Also engages in preliminary discussions with number of funding parnters, to explore equity and debt options. CEO & Technical Director Bill Brodie Good says: "The development aspects of the Hancock Iron Ore Project to be shovel ready for early 2023 are progressing very well. We are on track to have all the permitting in place, and will soon be in a position to commence mining next year. Additionally, in-depth discussions with third party contractors and potential offtake partners to enable us to get into production in 2023 are continuing."

----------

Omega Diagnostics Group PLC - Alva, Scotland-based diagnostics company - Raises GBP4.1 million in placing, subscription and open offer at issue price of 4 pence per new ordinary share. Fundraise remains conditional on the approval by shareholders at the general meeting to be held on June 6.

----------

t42 IoT Tracking Solutions PLC - Jersey-based provider of tracking, security and monitoring solutions for containers and freight - Completes pilot with security division of Philip Morris Israel Ltd, and completes commercial delivery of 200 Lokies to IoT provider. Also says DB Schenker will start initial pilot program with its tracking locks.

----------

Ncondezi Energy Ltd - Mozambique-based power development company - Says Seritza Ltd extends period in which it will not call up working capital facility term loan to June 30, while Ncondezi finalises restructuring talks.

----------

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Doses first patient in phase 3 Connect clinical trial for US and Japanese markets, with headline data from the trial expected in 2023. The trial will investigate hydrocortisone modified-release hard capsules DNL-0200 for adults with congenital adrenal hyperplasia, as compared with immediate release hydrocortisone. "I am delighted that we have dosed the first patient in this important clinical trial. CONnECT builds on knowledge gained from our European study for DNL-0200, to date the largest ever completed study in CAH, and as the first blinded study, CONnECT should prove to be the definitive evidence for optimal treatment of patients with CAH," says CEO Richard Bungay.

----------

Fulcrum Utility Services Ltd - Sheffield, England-based utility infrastructure and services - Completes tranche five of the domestic gas assets transfer to ES Pipelines Ltd for a total consideration of GBP2.1 million. Has received GBP2 million cash, and expects retention balance of GBP100,000 next November. Total gross consideration for the assets is expected at around GBP49 million, with GBP30.7 million received to date.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com and Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 Dec 2019 13:19

Diurnal submits application for 'Alkindi Sprinkle' to US FDA

(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of 'Alkindi Sprinkle', or hydrocortisone granules in capsules for opening, as a replacement therapy of adrenal insufficiency in infants, children and adolescents in the US, it announced on Monday.

Read more
21 Nov 2019 11:36

Diurnal Primary Focus Remains On Progressing Flagship Products

Diurnal Primary Focus Remains On Progressing Flagship Products

Read more
20 Nov 2019 11:36

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Read more
24 Sep 2019 11:21

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Read more
14 Jun 2019 14:26

Diurnal Shareholders Approve Placing, Open Offer Worth GBP6 Million (ALLISS)

(Alliance News) - Pharmaceutical firm Diurnal Group PLC's shareholders on Friday approved its GBP5.9 million fundraise completed earlier in the day.Diurnal, which focuses on patients or

Read more
28 May 2019 13:32

Diurnal Group launches placing and open offer to fund drug development

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to progress the development and commercialisation of its products.

Read more
28 May 2019 10:49

Diurnal Raises GBP5 Million Via Placing; Plans GBP1 Million Open Offer (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said Tuesday it has raised around GBP5.4 million via a 20.6 million share placing priced at 26 pence per share and announced an open offer to raise up to

Read more
10 May 2019 09:36

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed a

Read more
24 Apr 2019 15:50

Diurnal gets orphan drug designation for Alkindi in Australia

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug designation in Australia by the Therapeutic Goods Administration, for the indication 'replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents from birth to 18 years old'.

Read more
24 Apr 2019 10:44

Diurnal Gets Orphan Drug Designation For Alkindi In Australia

LONDON (Alliance News) - Diurnal Group PLC on Wednesday said its adrenal insufficiency drug Alkindi has been granted a second patent and orphan drug designation in Australia.Shares in were

Read more
28 Mar 2019 08:35

Diurnal soars after securing Nordic distribution deal

(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.

Read more
21 Mar 2019 16:11

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 22 March Sanne GroupFull Year ResultsSmiths GroupHalf Year BootFull Year

Read more
20 Mar 2019 10:33

Diurnal Group upbeat following FDA meeting over 'Alkindi'

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a new drug application (NDA) for 'Alkindi' (hydrocortisone granules in capsules for opening) in the fourth quarter of 2019 as previously planned, with final acceptance of the filing by the FDA expected in 2020.

Read more
25 Feb 2019 10:39

Diurnal expecting Israel launch of 'Alkindi' next year

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application (MAA) for its 'Alkindi' (hydrocortisone granules in capsules for opening) product to the Ministry of Health in Israel.

Read more
10 Jan 2019 12:35

Diurnal Granted US Patent But Unsure Why Share Price Has Tripled

LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.Shares were 188% higher on Thursday

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.